Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma GmbhfiledCriticalAdverio Pharma Gmbh
Priority claimed from PCT/EP2014/053096external-prioritypatent/WO2014128109A1/fr
Publication of MA38350A1publicationCriticalpatent/MA38350A1/fr
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
La présente invention porte sur des formes du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}méthylcarbamate de méthyle, comprenant sa modification i, sa modification ii, son monosolvate avec du dmso, son sesquisolvate avec du dmso et son 1/4 de solvate avec de l'acétate d'éthyle.
MA38350A2013-02-212014-02-18Formes du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}méthylcarbamate de méthyle
MA38350A1
(fr)
Compuestos de fórmula genérica 4-(8-metoxi-1-(1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H- imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y sus sales.
Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
History of n-(2, 3-dihydro-1h-pyrrolo [3,2-b] pyridine-5-yl)-4-quinazolinamine and n-(2, 3-dihydro-1h-indole-5-yl} – 4-quinazolinamine as perk inhibitors
Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.